ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation.
The purpose of the present study was to evaluate the correlation between repair cross-complementing group-1 (ERCC1) status and the outcome of platin-based chemoradiation of locally advanced cervical cancer. Tumor specimens from 112 patients with locally advanced cervical cancer were evaluated for ERCC1 expression. The outcome of these patients was retrospectively assessed in correlation with ERCC1 expression. Increased expression of ERCC1 correlates with a better prognosis of cervical cancer. The 2-year overall survival was 68.6% in the group with low H-score for ERCC-1 and gradually increased in the intermediate and high H-score groups to 71.7% and 90.7%, respectively. The present study did not confirm the correlation of low levels of ERCC1 expression with unfavorable outcomes of patients with locally advanced cervical cancer treated with platin-based radiochemotherapy.